The most notable thing about TypeScript 6.0 is that it's going to be the last release based on the current JavaScript ...
It is now 21 years since graphene - the "miracle" material made in Manchester - was first shown to the world by two academics who discovered it when they were playing with sticky tape one night. The ...
I can't stand opening the Microsoft Store. It's slow to load, confusing to browse, and full of ads for things I don't care about. Luckily, thanks to a new feature, I don't have to open the Microsoft ...
Green hydrogen production technology, which utilizes renewable energy to produce eco-friendly hydrogen without carbon emissions, is gaining attention as a core technology for addressing global warming ...
While Bethesda has made its position very clear on Fallout game locations (it'll never stray outside of the United States) that doesn't stop people dreaming about exploring irradiated wastelands in ...
Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...
PgAdmin often fails to install or launch on Windows 11 due to a combination of strict Windows file permissions and software conflicts. The app struggles to create or access its configuration files in ...
Artificial-intelligence workloads are pushing semiconductor design to a point where traditional scaling strategies are running out of room. Performance improvements that once came from shrinking ...
Like their conventional counterparts, quantum computers can also break down. They can sometimes lose the atoms they manipulate to function, which can stop calculations dead in their tracks. But ...
Proton exchange membrane fuel cells (PEMFCs) are widely regarded as a clean and efficient energy conversion technology, particularly for electric vehicles and portable power systems. However, their ...
Atom’s lingdolinurad (ABP-671), a URAT1 inhibitor, is in late stage global clinical trials for chronic gout and ABP-745, an anti-inflammatory drug, is in multi-country Phase 2 trials for acute gout ...